David Dillon
Has grant
Assistant Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
David Dillon is an Assistant Professor at the University of California Davis Medical Center in the United States. His research primarily focuses on emergency medicine, specifically in the areas of cardiac arrest management, resuscitation, and the associated systemic disparities in healthcare. Recent publications include studies on prehospital care guidelines, randomized trials in cardiac arrest, and the impact of naloxone on out-of-hospital cardiac arrests.
Recent Grants
Grant: Close
Improving the Identification of Opioid-Associated Out-of-Hospital Cardiac Arrest
Open Date: 2023-09-01
Close Date: 2025-08-31
Articles (14)
Objective Despite frequent treatment of alcohol withdrawal syndrome (AWS) in the emergency department (ED), evidence for phenobarbital (PB) as an ED alternative therapy is mixed. We conducted a systematic review and meta‐analysis comparing safety and efficacy of PB to benzodiazepines (BZDs) for treatment of AWS in the ED. Methods We searched articles and references published in English in PubMed, Web of Science, and Embase from inception through May 2022. We included randomized trials and cohort studies comparing treatment with PB to BZD controls and excluded studies focused on non‐AWS conditions. Review was conducted by two blinded investigators and a third author; eight of 59 (13.6%) abstracts met inclusion criteria for review and meta‐analysis using a random‐effects model. Treatment superiority was evaluated through utilization, pharmacologic, and clinical outcomes. Primary outcomes for meta‐analysis were the proportion of patients (1) admitted to the intensive care unit (ICU), (2) admitted to the hospital, (3) readmitted to the ED after discharge, and (4) who experienced adverse events. Results Eight studies (two randomized controlled trials, six retrospective cohorts) comprised data from 1507 patients in 2012 treatment encounters for AWS. All studies were included in meta‐analysis for adverse events, seven for hospital admission, five for ICU admission, and three for readmission to the ED after discharge. Overall methodological quality was low‐moderate, risk of bias moderate‐high, and statistical heterogeneity moderate. Pooled relative risk of ICU admission for those treated with PB versus BZD was 0.92 (95% confidence interval [CI] 0.54–1.55). Risk for admission to the hospital was 0.98 (95% CI 0.89–1.07) and for any adverse event was 1.1 (95% CI 0.78–1.57); heterogeneity prevented meta‐analysis for ED readmission. Conclusions The current literature base does not show that treatment with PB significantly reduces ICU admissions, hospital admissions, ED readmissions, or adverse events in ED patients with AWS compared with BZDs alone.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Collaborators (6)
Sean Callahan
Associate Professor
University of Utah
Ralph Wang
Associate Clinical Professor
University of California, San Francisco
Kirby Mayer
Assistant Professor
University of Kentucky
Shijing Jia
University of Michigan
Charles E. Murphy
-
Vidya Eswaran
Assistant Professor
Baylor College of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.